Early empiric antibiotic use in COVID-19 patients: results from the international VIRUS registry
SUMMARY
International Journal of Infectious Diseases | December 19, 2023
With the increased demand for hospitalization that COVID-19 generated around the world, came the escalation of inappropriate antibiotic use.
Results from the Society of Critical Care Medicine Discovery VIRUS international COVID-19 Registry aim to determine the rate and factors associated with early empiric antibiotic (EEAB) treatment to help set goals for antimicrobial stewardship efforts, in the post-pandemic era.
Featured Experts
Uluhan Sili MD, PhD, Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Türkiye
Aysun Tekin MD, Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Huseyin Bilgin MD, MPH, Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Türkiye et al
GET STARTED
Read more about this important research ➡
PUBLISHED ON
May 6, 2024
